When the Business Times broke the story that Amgen was cutting roughly 500 support and operations jobs at its sprawling Thousand Oaks campus, there were gasps — and sighs of relief. Gasps because the world’s largest biotechnology company is the economic engine for the Conejo Valley, East Ventura County and, for that matter, a big Read More →
Nearly 500 Amgen employees in Thousand Oaks have been notified that they will be re-assigned, relocated or laid off as part of a restructuring plan. The biotech giant informed employees on March 22 that they will be reassigned to a new Tampa Bay, Fla. facility and research and development offices in Cambridge, Mass. and South Read More →
Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
The board of directors for Thousand Oaks biotechnology company Amgen declared a $1.15 per share dividend March 3 for the second quarter of 2017. The dividend will be paid on June 8 to all stockholders of record as of the close of business on May 17. The company has a market cap of $130.1 billion Read More →
Amgen’s new leukemia drug Blincyto increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. Results from its Phase 3 Tower study revealed that Blincyto almost doubled median overall survival versus chemotherapy among adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic Read More →
Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →